A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 3
- Study design
- RANDOMIZED · PARALLEL · PREVENTION · NONE
- Evidence population
- Human clinical study registration
- Participants
- 324
- Population
- ALL · 50 Years to 70 Years
- Duration
- 2023-11-28 to 2028-11-28
- Intervention
- Grafalon; Thymoglobulin
- Comparator
- Anti-T lymphocyte globulin (ATLG); Anti Thymocyte Globulins (ATG)
- Outcomes measured
- Incidence of grade II-IV acute Graft Versus Host Disease (GVHD) according to the Mount Sinai Acute GVHD International C…; Number of patients with at least 3 consecutive days with neutrophils > 0.5 G/L and platelets > 20 G/L — Up to 24 months; T, B, NK, regulatory T cell and gammaglobulin levels in the peripheral blood — 1 month after transplantation; T, B, NK, regulatory T cell and gammaglobulin levels in the peripheral blood — 100 days after transplantation; T, B, NK, regulatory T cell and gammaglobulin levels in the peripheral blood — 6 months after transplantation; T, B, NK, regulatory T cell and gammaglobulin levels in the peripheral blood — 12 months after transplantation; T, B, NK, regulatory T cell and gammaglobulin levels in the peripheral blood — 24 months after transplantation; Percentage of chimerism — 1 month after transplantation; Percentage of chimerism — 100 days after transplantation; Percentage of chimerism — 6 months after transplantation; Percentage of chimerism — 12 months after transplantation; Incidence of grade I acute GVHD — Up to 24 months; Incidence of chronic GVHD — 12 months after transplantation; Incidence of chronic GVHD — 24 months after transplantation; Incidence of relapse — 12 months after transplantation; Incidence of relapse — 24 months after transplantation; Progression free survival — 12 months after transplantation; Progression free survival — 24 months after transplantation; Number of severe infections — 100 days after transplantation; Number of severe infections — 12 months after transplantation
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Stem cells · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Title supplies ageing or longevity context.
Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.